Equities
Health CareMedical Equipment and Services
  • Price (EUR)213.50
  • Today's Change9.50 / 4.66%
  • Shares traded67.07k
  • 1 Year change-25.14%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 14:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform7
Hold11
Sell1
Strong Sell3

Share price forecast in EUR

The 24 analysts offering 12 month price targets for Sartorius AG have a median target of 266.10, with a high estimate of 350.00 and a low estimate of 170.00. The median estimate represents a 30.44% increase from the last price of 204.00.
High71.6%350.00
Med30.4%266.10
Low-16.7%170.00

Dividends in EUR

Historical dividend information is not available for Sartorius AG.
Div growth (TTM)-48.95%
More ▼

Earnings history & estimates in EUR

On Oct 17, 2024, Sartorius AG reported 3rd quarter 2024 earnings of 0.87 per share. This result was in line with the consensus of the 7 analysts following the company and under-performed last year's 3rd quarter results by 16.35%.
Average growth rate-3.29%
Sartorius AG reported annual 2023 earnings of 4.94 per share on Feb 16, 2024.
Average growth rate+24.30%
More ▼

Revenue history & estimates in EUR

-32768 had 3rd quarter 2024 revenues of 793.60m. This missed the 814.93m consensus estimate of the 7 analysts following the company. This was 12.13% below the prior year's 3rd quarter results.
Average growth rate-0.38%
-32768 had revenues for the full year 2023 of 3.40bn. This was 18.66% below the prior year's results.
Average growth rate+19.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.